Arimidex

Anastrozole is the most commonly available and well-understood reversible AI. It is chosen when on-cycle aromatization is confirmed or suspected to be producing symptoms, and when the user wants a compound that can be precisely titrated and corrected quickly.

The reversible mechanism is useful: if the dose is too high, reducing it allows estrogen to recover within days.

Use case: On-cycle estrogen control when there is real evidence of excess aromatization.

Administration: Start low and titrate from symptoms plus labs, not fear.

Decision rule: The correct dose is the lowest dose that solves the problem. Preventive daily use is how users crash estrogen.

Stop or reduce if: joints dry out, libido drops, or the user becomes flat and irritable.

With a 48-hour half-life, anastrozole reaches steady-state in approximately 7 days. The full estrogen-lowering effect is not immediate on day one. Users who take it as needed (not daily) should understand that blood level variability affects consistency of effect.

Anastrozole is a non-steroidal, reversible aromatase inhibitor. It competes with androgens for the aromatase enzyme binding site, reducing the conversion rate of testosterone and androstenedione to estrogen. Its effects are dose-dependent and reversible, stopping or reducing the dose allows aromatase activity to return to baseline relatively quickly (within 1–3 days given the 48-hour half-life).

The key principle for anastrozole use is that estrogen has important physiological roles that extend beyond gynecomastia prevention. At appropriate levels, estrogen supports joint lubrication, cardiovascular health, bone density, libido, and mood. Over-suppression (“crashing” estrogen) produces a characteristic symptom cluster: dry, achy joints, flatness and anhedonia, low libido, poor sleep, and reduced training pump. These symptoms are often mistaken for low testosterone, leading users to incorrectly escalate androgen dose.

Labs vs. symptoms: Anastrozole dosing should be guided by estradiol bloodwork, not by the absence of gynecomastia symptoms. A user can have estrogen in an optimal range and still not develop gynecomastia. Conversely, a user can have crashed estrogen and still have no nipple sensitivity. Symptoms and labs together tell the full story.

Starting at 0.5mg or 1mg daily without bloodwork, then spending weeks managing symptoms of low estrogen while believing the original problem was too-high estrogen.

The correct starting approach: use the minimum dose needed, with labs confirming estradiol is in range rather than using nipple sensitivity or water retention as the sole feedback signal. Target estradiol is approximately 20–30 pg/mL on cycle for most users, though this varies by individual response.

Not adjusting dose when testosterone dose changes. Higher testosterone → more aromatization → more AI needed. Lower testosterone → less. Many users set-and-forget AI dose when testosterone dose was changed.

Compared with Aromasin, anastrozole is more easily titrated because its effects are reversible. If anastrozole is overdosed, reducing or stopping it allows estrogen to recover within a few days. Exemestane’s irreversible binding means recovery depends on new aromatase enzyme production.

Compared with Tamoxifen, anastrozole reduces the amount of estrogen present in the body, while tamoxifen blocks estrogen from binding at the breast. These address different problems and are sometimes used together for different reasons.